U.S. markets closed
  • S&P 500

    +72.88 (+1.73%)
  • Dow 30

    +424.38 (+1.27%)
  • Nasdaq

    +267.27 (+2.09%)
  • Russell 2000

    +41.36 (+2.09%)
  • Crude Oil

    -2.46 (-2.61%)
  • Gold

    +11.70 (+0.65%)
  • Silver

    +0.49 (+2.39%)

    -0.0068 (-0.66%)
  • 10-Yr Bond

    -0.0390 (-1.35%)

    -0.0064 (-0.52%)

    +0.4810 (+0.36%)

    +713.28 (+2.98%)
  • CMC Crypto 200

    +3.36 (+0.59%)
  • FTSE 100

    +34.98 (+0.47%)
  • Nikkei 225

    +727.65 (+2.62%)
  • Oops!
    Something went wrong.
    Please try again later.

Why the Farm Bill could make 2019 the year of CBD

·Senior Writer
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Cannabis is coming in 2019.

For starters, there’s the obvious and expected boost from states that voted to legalize recreational marijuana in 2018. But perhaps more impactful than that could be the effects of the recently agreed upon Farm Bill, which would legalize hemp and the hemp-derived extract called cannabidiol, or CBD, on a federal level.

That change, which would remove the hurdle CBD companies share with marijuana companies, could trigger a CBD “exploding point,” according to cannabis research firm Brightfield Group, which foresees CBD sales growing 40 times larger than the nearly $600 million posted in 2018 by 2022. Right now, CBD and marijuana companies have to operate in a legal grey area, on a state-by-state basis.

“We saw 80% growth in CBD this year and that was just from small- and mid-size retailers,” Brightfield Group Director of Research Bethany Gomez told Yahoo Finance. “Now that larger retailers are already putting together their plans for what CBD products to carry, we expect the CBD market to hit $22 billion by 2022.”

That forecast amounts to a five-year compounded annual growth rate of 132%.

CBD, largely derived from marijuana’s non-intoxicating cousin hemp, has increasingly been infused in everything from creams and oils to edibles and drinks for supposed health benefits. So far, the U.S. Food & Drug Administration has been muted in policing most of the claims associated with CBD products, but that could change according to National Hemp Association Chairman Geoff Whaling.

“We don’t know what the FDA will do on CBD, that’s kind of an unknown right now,” he said. “But how do you put that genie back in the bottle?”

What will the FDA do?

In June, the FDA approved the market’s first CBD drug, a treatment option for severe cases of epilepsy, leading some to believe the agency might be pressured to more aggressively police non-approved CBD products moving forward.

For what it’s worth, the proposed Farm Bill includes language from Sen. Mitch McConnell's Hemp Farming Act that would remove CBD from the list of Schedule I controlled substances. That change, which could happen as soon as the Farm Bill passes, would make hemp and CBD legal on a federal level, but would still leave CBD at the mercy of the FDA when it comes to being included as an ingredient in certain products including edibles and drinks.

“Language in the Hemp Farming Act of 2018 actually gives oversight back to the FDA on all things from the hemp crop,” Whaling said.

Some of the fastest-growing CBD categories Brightfield Group expects to see are the non-ingestible dominant areas of beauty, skincare, and topicals. Though there are a growing number of names in those spaces, Gomez said the CBD market as a whole is starting to see some consolidation at the top. Last year, sales among the top 20 hemp CBD companies accounted for one-third of the market. In 2018, the share controlled by the top 20 companies grew to two-thirds of the market.

“Those are the brands that are going to be able to make it to the shelves of Target, Walgreens, and CVS,” she said. “They are also the ones best suited to complete the required tests to win any necessary approvals.”

Boulder, Colorado-based market leader Charlotte's Web, which completed its Canadian initial public offering this summer and trades in the U.S. under the OTC ticker “CWBHF,” accounted for 12% of the total market with $40 million in sales in 2017. Last week, the company announced it notched a third-quarter gross profit of $13.8 million.

Las Vegas-based CV Sciences, which excels in CBD soft gels and capsules sold through natural food stores, trails slightly behind with a 11% market share, according to Brightfield Group data. Medical Marijuana Inc. rounds out the top three CBD companies, accounting for 10% of the market.

The Farm Bill could be passed as early as mid-December with the removal of CBD from the Schedule I list happening around the same time. That could trigger a big wave of investment in the space as hemp production in the U.S. becomes legal for the first time in nearly 50 years.

“It removes hemp from the controlled substances list — which opens up banking — which opens it up to being a cash commodity,” Whaling said. “Once the federal Farm Bill passes, those barriers are going to be removed and the floodgates will be opened.”

Zack Guzman is a senior writer and on-air reporter covering entrepreneurship, startups, and breaking news at Yahoo Finance. Follow him on Twitter @zGuz.

Read more:

Juul surpasses Facebook as fastest startup to reach decacorn status

How Juul became the FDA’s latest target

Joe Camel illustrator: E-cig maker Juul’s marketing ‘seems more egregious’